References
- Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079–1082.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
- Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417.
- Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888.
- Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
- Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
- Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119.
- Paasinen-Sohns A, Koelzer VH, Frank A, et al. Single-center experience with a targeted next generation sequencing assay for assessment of relevant somatic alterations in solid tumors. Neoplasia. 2017;19(3):196–206.
- Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2017;19(3):341–365.
- Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J Mol Diagn. 2017;19(1):4–23.
- NHGRI Genome Sequencing Program. DNA sequencing costs. [ Available from: https://www.genome.gov/sequencingcostsdata], last accessed on 2018 Jul 17.
- Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.
- Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–1889.
- Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018;36(16):1631–1641.
- FDA. List of cleared or approved companion diagnostic devices. [ Available from: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm], last accessed on 2018 Jul 17.
- Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
- Condorelli R, Spring L, O’Shaughnessy J, Lacroix L, Bailleux C, Scott V, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2017;29(3):640–645.
- Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
- Klein-Scory S, Maslova M, Pohl M, et al. Significance of liquid biopsy for monitoring and therapy decision of colorectal cancer. Transl Oncol. 2018;11(2):213–220.
- Weinstein IB. Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science. 2002;297(5578):63–64.
- Ioannidis JPA, Khoury MJ. Evidence based medicine and big genomic data. Hum Mol Genet. 2018;27(R1):R2–R7.
- Jain A The 5 Vs of Big Data 2016. Available from: https://www.ibm.com/blogs/watson-health/the-5-vs-of-big-data], last accessed on 2018 Jul 17.
- Mesko B. The role of artificial intelligence in precision medicine. Expert Rev Precision Med Drug Dev. 2017;2(5):239–241.
- Kohn MS, Sun J, Knoop S, et al. IBM’s health analytics and clinical decision support. Yearb Med Inform. 2014;9:154–162.
- Wang D, Khosla A, Gargeya R, et al. Deep learning for identifying metastatic breast cancer. Quantitative Methods. 2016;arXiv:1606.05718.
- Broes S, Lacombe D, Verlinden M, et al. Toward a tiered model to share clinical trial data and samples in precision oncology. Front Med (Lausanne). 2018;5:6.
- Jensen MA, Ferretti V, Grossman RL, et al. The NCI genomic data commons as an engine for precision medicine. Blood. 2017;130(4):453–459.
- AACR. Project GENIE [ Available from: http://www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx], last accessed on 2018 Jul 17.
- Miller RS, Wong JL. Using oncology real-world evidence for quality improvement and discovery: the case for ASCO’s CancerLinQ. Future Oncol. 2018;14(1):5–8.
- Gan HK, You B, Pond GR, et al. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst. 2012;104(8):590–598.
- Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483(7391):531–533.
- Korn EL, Freidlin B. Adaptive clinical trials: advantages and disadvantages of various adaptive design elements. J Natl Cancer Inst. 2017;109:6.
- Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100.
- Kaplan R, Maughan T, Crook A, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol. 2013;31(36):4562–4568.
- Herbst RS, Gandara DR, Hirsch FR, et al. Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514–1524.
- Von Hoff DD, Stephenson JJ Jr., Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877–4883.
- Califano A Precision Medicine Initiative 2018 [ Available from: http://califano.c2b2.columbia.edu/n-of-1-clinical-trials-precision-medicine-cancer], last accessed on 2018 Jul 17.
- Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168(4):584–599.
- Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–713.
- Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373–6383.
- Tsimberidou AM, Wen S, Hong DS, et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014;20(18):4827–4836.
- Tsimberidou AM, Hong DS, Ye Y, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson precision medicine study. JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002
- Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014;61–69.
- ClinicalTrials.gov. IMPACT2 2014 [ Available from: https://clinicaltrials.gov/ct2/show/NCT02152254], last accessed on 2018 Jul 17.
- Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334.
- Tsimberidou AM, Kurzrock R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015;16(16):e579–80.
- Rodon J, Soria JC, Berger R, et al. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015;26(8):1791–1798.
- ClinicalTrials.gov. NCI-MATCH 2015 [ Available from: https://clinicaltrials.gov/ct2/show/NCT02465060], last accessed on 2018 Jul 17.
- ClinicalTrials.gov. NCI-MPACT 2013 [ Available from: https://clinicaltrials.gov/ct2/show/NCT01827384], last accessed on 2018 Jul 17.
- ClinicalTrials.gov. TAPUR 2016 [ Available from: https://clinicaltrials.gov/ct2/show/NCT02693535], last accessed on 2018 Jul 17.
- Chen AP, Williams M, Kummar S, et al. Feasibility of molecular profiling based assignment of cancer treatment (MPACT): A randomized NCI precision medicine study. J Clin Oncology. 2016;34(15_suppl):2539.
- Krop I, Jegede O, Grilley-Olson J, et al. Results from molecular analysis for therapy choice (MATCH) arm I: taselisib for PIK3CA-mutated tumors. J Clin Oncol. 2018;36(suppl):abstr 101.
- Jhaveri K, Makker V, Wang X, et al. Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. J Clin Oncol. 2018;36(suppl):abstr 100.
- Chae Y, Vaklavas C, Cheng H, et al. Molecular analysis for therapy choice (MATCH) arm W: phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. J Clin Oncol. 2018;36(suppl):abstr 2503.
- Azad N, Overman M, Gray R, et al. Nivolumab in mismatch-repair deficient (MMR-d) cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice). J Immunother Cancer. 2017;89(5,Supp):13.
- ClinicalTrials.gov. The Drug Rediscovery Protocol (DRUP Trial). [ Available from: https://clinicaltrials.gov/show/NCT02925234], last accessed on 2018 Jul 17.
- Buzyn A, Blay JY, Hoog-Labouret N, et al. Equal access to innovative therapies and precision cancer care. Nat Rev Clin Oncol. 2016;13(6):385–393.
- Sindzinski A. The Moonshot Initiative and the Future of Cancer Research. J Natl Cancer Inst. 2017;109:12.
- U.S. Department of Health & Human Services. Precision medicine initiative cohort program [ Available from: https://www.nimhd.nih.gov/programs/collab/pmi], last accessed on 2018 Jul 17.
- NIH/NCI. NCI-sponsored trials in precision medicine [ Available from: https://dctd.cancer.gov/majorinitiatives/NCI-sponsored_trials_in_precision_medicine.htm], last accessed on 2018 Jul 17.
- European Commission. Seventh Framework Program [ Available from: https://ec.europa.eu/research/fp7/index_en.cfm], last accessed on 2018 Jul 17.
- Innovative Medicines Initiative. European Union public-private partnership funding health research and innovation. [ Available from: http://www.imi.europa.eu], last accessed on 2018 Jul 17.
- Cancer Core Europe. European cancer association for innovative research. [ Available from: https://www.cancercoreeurope.eu], last accessed on 2018 Jul 17.
- Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
- Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608.
- FDA. Pembrolizumab for first tissue/site agnostic indication 2017 [ Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm], last accessed on 2018 Jul 17.
- Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33(5):853–861.
- Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68.
- ClinicalTrials.gov. ACTolog study [ Available from: https://clinicaltrials.gov/ct2/show/NCT02876510], last accessed on 2018 Jul 17.